Free Trial

Celularity (CELU) Competitors

Celularity logo
$2.10 -0.23 (-9.87%)
Closing price 04:00 PM Eastern
Extended Trading
$2.10 +0.00 (+0.24%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CELU vs. FTLF, NKTX, CYBN, TNGX, NLTX, EPRX, ACRS, ADCT, LRMR, and EDIT

Should you be buying Celularity stock or one of its competitors? The main competitors of Celularity include FitLife Brands (FTLF), Nkarta (NKTX), Cybin (CYBN), Tango Therapeutics (TNGX), Neoleukin Therapeutics (NLTX), Eupraxia Pharmaceuticals (EPRX), Aclaris Therapeutics (ACRS), ADC Therapeutics (ADCT), Larimar Therapeutics (LRMR), and Editas Medicine (EDIT). These companies are all part of the "pharmaceutical products" industry.

Celularity vs.

Celularity (NASDAQ:CELU) and FitLife Brands (NASDAQ:FTLF) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, community ranking, media sentiment, dividends, profitability, valuation and risk.

19.0% of Celularity shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 22.1% of Celularity shares are owned by company insiders. Comparatively, 61.3% of FitLife Brands shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

FitLife Brands has a consensus price target of $20.50, indicating a potential upside of 47.48%. Given FitLife Brands' stronger consensus rating and higher probable upside, analysts clearly believe FitLife Brands is more favorable than Celularity.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celularity
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
FitLife Brands
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.33

FitLife Brands has a net margin of 13.38% compared to Celularity's net margin of -72.72%. FitLife Brands' return on equity of 28.03% beat Celularity's return on equity.

Company Net Margins Return on Equity Return on Assets
Celularity-72.72% -119.53% -25.40%
FitLife Brands 13.38%28.03%15.13%

Celularity has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, FitLife Brands has a beta of 0.9, meaning that its stock price is 10% less volatile than the S&P 500.

In the previous week, FitLife Brands had 6 more articles in the media than Celularity. MarketBeat recorded 7 mentions for FitLife Brands and 1 mentions for Celularity. Celularity's average media sentiment score of 0.68 beat FitLife Brands' score of 0.04 indicating that Celularity is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celularity
1 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
FitLife Brands
2 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

FitLife Brands has higher revenue and earnings than Celularity. Celularity is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Celularity$54.22M0.92-$196.29M-$2.65-0.79
FitLife Brands$64.47M2.02$5.30M$0.8416.55

Celularity received 5 more outperform votes than FitLife Brands when rated by MarketBeat users. However, 60.00% of users gave FitLife Brands an outperform vote while only 42.11% of users gave Celularity an outperform vote.

CompanyUnderperformOutperform
CelularityOutperform Votes
8
42.11%
Underperform Votes
11
57.89%
FitLife BrandsOutperform Votes
3
60.00%
Underperform Votes
2
40.00%

Summary

FitLife Brands beats Celularity on 16 of the 19 factors compared between the two stocks.

Get Celularity News Delivered to You Automatically

Sign up to receive the latest news and ratings for CELU and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CELU vs. The Competition

MetricCelularityPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$50.00M$6.48B$5.35B$8.38B
Dividend YieldN/A2.66%5.22%4.10%
P/E Ratio-0.798.9226.8419.71
Price / Sales0.92250.95391.39116.98
Price / Cash0.2465.8538.2534.62
Price / Book1.006.466.794.50
Net Income-$196.29M$143.98M$3.23B$248.18M
7 Day Performance3.96%3.04%4.07%1.14%
1 Month Performance38.16%7.44%12.52%15.20%
1 Year Performance-34.78%-2.46%16.83%6.56%

Celularity Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CELU
Celularity
0.1969 of 5 stars
$2.10
-9.9%
N/A-25.8%$50.00M$54.22M-0.79220News Coverage
FTLF
FitLife Brands
4.4273 of 5 stars
$15.41
-1.9%
$20.50
+33.0%
+0.9%$144.61M$64.47M18.2420Earnings Report
NKTX
Nkarta
1.9798 of 5 stars
$2.02
+4.7%
$14.83
+634.3%
-73.3%$143.34MN/A-1.07140News Coverage
Positive News
Earnings Report
Analyst Revision
Gap Up
CYBN
Cybin
2.7493 of 5 stars
$6.62
-6.1%
$86.00
+1,199.1%
N/A$142.18MN/A-1.5150News Coverage
TNGX
Tango Therapeutics
1.5872 of 5 stars
$1.31
+14.9%
$12.33
+841.5%
-73.0%$141.62M$42.07M-1.1190
NLTX
Neoleukin Therapeutics
N/A$14.73
-1.8%
N/A-42.6%$138.43MN/A-4.7490Gap Up
High Trading Volume
EPRX
Eupraxia Pharmaceuticals
2.2192 of 5 stars
$3.86
+1.4%
$10.50
+172.4%
+32.2%$138.20MN/A-5.3529Gap Up
ACRS
Aclaris Therapeutics
2.8746 of 5 stars
$1.25
-0.8%
$10.67
+753.3%
+13.4%$135.35M$18.72M-2.40100Gap Up
ADCT
ADC Therapeutics
2.675 of 5 stars
$1.35
+5.9%
$7.75
+476.2%
-47.8%$133.39M$70.84M-0.56310News Coverage
Earnings Report
Analyst Revision
LRMR
Larimar Therapeutics
2.0753 of 5 stars
$2.08
-1.9%
$19.63
+843.5%
-71.7%$133.18MN/A-1.8130Positive News
EDIT
Editas Medicine
4.2699 of 5 stars
$1.54
+6.2%
$5.73
+271.9%
-70.3%$128.91M$32.31M-0.60230Positive News
Gap Up

Related Companies and Tools


This page (NASDAQ:CELU) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners